Animace načítání

Stránka se připravuje...

Přihlásit se Registrovat se
28 056 právních předpisů

Další údaje zde

Technická podpora

Poskytujeme technickou podporu zdarma

Zavolejte nám

+420 777 717 492

Plné znění - 32022R0692

  1. Úvodní strana
  2. Právní předpisy EU
  3. Plné znění - 32022R0692

Na co čekáte? Nečekejte už ani minutu.
Získejte přístup na tento text ještě dnes. Kontaktujte nás a my Vám obratem uděláme nabídku pro Vás přímo na míru.

Chci získat výhodný přístup

XXXXXXXX KOMISE X&xxxx;XXXXXXXXX XXXXXXXXX (XX) 2022/692

xx xxx 16. února 2022,

xxxxxx xx xxx účely xxxxxxxxxxxx xxxxxxxxxxxxxxxxxx pokroku xxxx xxxxxxxx Xxxxxxxxxx xxxxxxxxxx x&xxxx;Xxxx (XX) x.&xxxx;1272/2008 o klasifikaci, xxxxxxxxxx x&xxxx;xxxxxx látek a směsí

(Text x&xxxx;xxxxxxxx pro XXX)

XXXXXXXX XXXXXX,

x&xxxx;xxxxxxx na Xxxxxxx x&xxxx;xxxxxxxxx Xxxxxxxx xxxx,

x&xxxx;xxxxxxx xx xxxxxxxx Xxxxxxxxxx xxxxxxxxxx a Rady (XX) x.&xxxx;1272/2008 xx dne 16.&xxxx;xxxxxxxx&xxxx;2008 x&xxxx;xxxxxxxxxxx, xxxxxxxxxx x&xxxx;xxxxxx xxxxx x&xxxx;xxxxx, x&xxxx;xxxxx x&xxxx;xxxxxxx xxxxxxx 67/548/XXX x&xxxx;1999/45/XX x&xxxx;x&xxxx;xxxxx xxxxxxxx (XX) č. 1907/2006 (1), x&xxxx;xxxxxxx xx xx.&xxxx;37 xxxx.&xxxx;5 uvedeného nařízení,

vzhledem x&xxxx;xxxxx xxxxxxx:

(1)

Xxxxxxx 3 x&xxxx;xxxxx 3 xxxxxxx XX xxxxxxxx (XX) x.&xxxx;1272/2008 xxxxxxxx seznam xxxxxxxxxxxxxxx xxxxxxxxxxx x&xxxx;xxxxxxxx xxxxxxxxxxxx látek xx xxxxxxx kritérií stanovených x&xxxx;xxxxxxx 2 xx 5 přílohy I uvedeného xxxxxxxx.

(2)

Xxxxxxxx xxxxxxxx pro xxxxxxxx xxxxx (xxxx xxx „agentura“) xxxx x&xxxx;xxxxxxx x&xxxx;xxxxxxx&xxxx;37 nařízení (XX) x.&xxxx;1272/2008 předloženy xxxxxx xx zavedení xxxxxxxxxxxxx xxxxxxxxxxx x&xxxx;xxxxxxxx xxxxxxxxx xxxxx x&xxxx;xx xxxxxxxxxxx xxxx zrušení xxxxxxxxxxxxxxx xxxxxxxxxxx x&xxxx;xxxxxxxx xxxxxxxxx jiných látek. Xxxx, xx Xxxxx xxx xxxxxxxxxx xxxxx (XXX) xxxxxxxx xxxxxxxxx xxxxxxxxxx zúčastněných xxxxx, xxxxxx x&xxxx;xxxxx xxxxxxx xxxxxxxxxxx xxxxxxxxxx&xxxx;(2):

—

xxxxxxxxxx xx xxx 5.&xxxx;xxxxxxxx&xxxx;2019 pro xxxxxxxxx, 1,1,1-xxxxxxxxx-X-(xxxxxxxxxxxxxx)-, xxxxxxxx xxxxxxxxx x&xxxx;xxxxxx křemičitým; xxxxxxxxx xxxxxxxxxx amorfní xxxx xxxxxxxxx v nanoformě x&xxxx;xxxxxxxxxx xxxxxxx,

—

xxxxxxxxxx xx xxx 4. května 2020 xxx xxxxxxxxxx (XXX), [(3-xxxxxx-4-xxxxxxxxxx)xxxxxxxxxx]-3-(2,2-xxxxxxxxxxxx)-2,2-xxxxxxxxxxxxxxxxxxx-1-xxxxxxxxxx,

—

xxxxxxxxxx xx xxx 4.&xxxx;xxxxxx&xxxx;2020 xxx β-cyfluthrin (XXX); xxxxxxx xxxx: xxx-(X)-xxxx(4-xxxxx-3-xxxxxxxxxxx)xxxxxx-(1X,3X)-3-(2,2-xxxxxxxxxxxxxx)-2,2-xxxxxxxxxxxxxxxxxxx-1-xxxxxxxxxx x&xxxx;xxx-(X)-xxxx(4-xxxxx-3-xxxxxxxxxxx)xxxxxx- (1X,3X)-3-(2,2-xxxxxxxxxxxxxx)-2,2-xxxxxxxxxxxxxxxxxxx-1-xxxxxxxxxx,

—

xxxxxxxxxx ze xxx 4.&xxxx;xxxxxx&xxxx;2020 xxx xxxxxxxxxxx (XXX); (1X)-X-[(6-xxxxxxxxxxxx-3-xx)xxxxxx]-X’-xxxx-X-xxxxxxxxxxxxxxxxxxx; (X)-X 1-[(6-chlor-3-pyridyl)methyl]-N 2-kyan-N 1-xxxxxxxxxxxxxxxx,

—

xxxxxxxxxx xx xxx 11.&xxxx;xxxxxx&xxxx;2020 xxx xxxxxx,

—

xxxxxxxxxx xx xxx 11.&xxxx;xxxxxx&xxxx;2020 xxx xxxx telluričitý,

—

stanovisko xx xxx 11.&xxxx;xxxxxx&xxxx;2020 xxx xxxxxxxxxxxxxx 2,2-xxxxxxxxxxxxxx-1-xxx; 3-xxxx-2,2-xxx(xxxxxxxxxx)xxxxxx-1-xx,

—

xxxxxxxxxx xx xxx 11.&xxxx;xxxxxx&xxxx;2020 xxx piperonylbutoxid (XXX); 5-{[2-(2-xxxxxxxxxxxx)xxxxxx]xxxxxx}-6-xxxxxx-1,3-xxxxxxxxxxx,

—

xxxxxxxxxx xx xxx 11.&xxxx;xxxxxx&xxxx;2020 pro xxxxxxxxxx,

—

xxxxxxxxxx ze xxx 11.&xxxx;xxxxxx&xxxx;2020 xxx xxx-1,7,7-xxxxxxxxxxxxxxxx[2.2.1]xxxx-2-xx-xxxxxxx; xxxxxxxxx-xxxxxxx,

—

xxxxxxxxxx xx xxx 11.&xxxx;xxxxxx&xxxx;2020 pro daminozid (XXX); 4-(2,2-xxxxxxxxxxxxxxxxx)-4-xxxxxxxxxxxx xxxxxxxx; X-(xxxxxxxxxxxxx)xxxxxxxxxxxx xxxxxxxx,

—

xxxxxxxxxx xx xxx 11.&xxxx;xxxxxx&xxxx;2020 xxx xxxxxxxxxxx (XXX); 3,6-bis(o-chlorfenyl)-1,2,4,5-tetrazin,

—

stanovisko xx dne 11.&xxxx;xxxxxx&xxxx;2020 xxx fluopikolid (ISO); 2,6-xxxxxxx-X-[3-xxxxx-5-(xxxxxxxxxxxxxx)-2-xxxxxxx]xxxxxxxxxxxxxx,

—

xxxxxxxxxx ze xxx 11.&xxxx;xxxxxx&xxxx;2020 pro xxxxxxxxxxxxx,

—

xxxxxxxxxx xx xxx 11.&xxxx;xxxxxx&xxxx;2020 xxx 2-xxxxxxxxxxxxxx xxxxxxxx x&xxxx;xxxx soli,

—

stanovisko xx xxx 11.&xxxx;xxxxxx&xxxx;2020 xxxxxxx xxxxxxxxxx xxxxxxxxx xxxxxxxx xxxxxxxx {[(karboxymethyl)imino]bis(ethylennitrilo)}tetraoctové xxxxxxxx x&xxxx;xxxxxx pentasodných x&xxxx;xxxxxxxxxxxxxxx xxxx na xxxxxx Xxxxxxxx xxxxxx,

—

xxxxxxxxxx xx xxx 17.&xxxx;xxxx&xxxx;2020 pro xxxxxxxxxx-xxx(2-xxxxxxxxxxxxx),

—

xxxxxxxxxx ze xxx 17.&xxxx;xxxx&xxxx;2020 xxx dibutylcín-diacetát,

—

stanovisko xx xxx 17.&xxxx;xxxx&xxxx;2020 xxx tetraoxid xxxxxxx-xxxxxxxx,

—

xxxxxxxxxx xx xxx 17.&xxxx;xxxx&xxxx;2020 xxx xxxxxxxxxxx (XXX); 2-xxxxx-3-xxxxx-1,4-xxxxxxxxxxx,

—

xxxxxxxxxx xx dne 17.&xxxx;xxxx&xxxx;2020 pro 4,4’-oxydi(benzensulfonohydrazid),

—

stanovisko xx xxx 17.&xxxx;xxxx&xxxx;2020 xxx toluen-4-sulfonohydrazid,

—

stanovisko xx xxx 17. září 2020 xxx xxxxxxxxx; 1,3-dimethyl-3,7-dihydro-1H-purin-2,6-dion,

—

stanovisko xx xxx 17. září 2020 pro 1,3-xxx(1-xxxxxxxxxx-1-xxxxxxxxxxx)xxxxxx; [x-XXXXX],

—

xxxxxxxxxx ze xxx 17. září 2020 xxx 1,3-xxx(xxxxxxxxxxxxxxxx)xxxxxx; [x-XXX],

—

xxxxxxxxxx ze xxx 17. září 2020 xxx 2,4,6-xxxxxxxxxxxx-x-xxxxxxx-xxxxxxxxxxx,

—

xxxxxxxxxx ze xxx 17.&xxxx;xxxx&xxxx;2020 pro triamid xxxxxxxx N-(2-nitrofenyl)fosforečné,

—

stanovisko ze xxx 17. září 2020 xxx xxxxx,

—

xxxxxxxxxx ze xxx 17.&xxxx;xxxx&xxxx;2020 pro 2-ethyl-2-{[(1-oxoallyl)oxy]methyl}propan-1,3-diyl-diakrylát; 2,2-xxx(xxxxxxxxxxxxxxxxx)xxxxx-xxxxxxx; xxxxxxxxxxxxxxxxx-xxxxxxxxxx,

—

xxxxxxxxxx ze xxx 17.&xxxx;xxxx&xxxx;2020 pro 1,5-xxxxxxxxxxxxxxxxxxxx [xxxxxxxxxx &xx;&xxxx;0,1&xxxx;% xxxx. xxxxxx x&xxxx;xxxxxxxxxxxxxx xxxxxxxx xxxxxx než 50 μm],

—

stanovisko xx xxx 17. září 2020 xxx 1,5-xxxxxxxxxxxxxxxxxxxx [obsahující ≥&xxxx;0,1&xxxx;% xxxx. částic x&xxxx;xxxxxxxxxxxxxx xxxxxxxx menším než 50 μx],

—

xxxxxxxxxx ze xxx 8.&xxxx;xxxxx&xxxx;2020 xxx xxxxxx amonný,

—

stanovisko xx xxx 8.&xxxx;xxxxx&xxxx;2020 xxx 2,4,6-xxx-xxxx-xxxxxxxxxx,

—

xxxxxxxxxx xx dne 8.&xxxx;xxxxx&xxxx;2020 xxx xxxxxxxxx (XXX); 2,6-dichlor-4-(3,3-dichlorallyloxy)fenyl{3-[5-(trifluormethyl)-2-pyridyloxy]propyl}ether,

—

stanovisko xx xxx 8.&xxxx;xxxxx&xxxx;2020 xxx xxxxxxx-2-xxxxx-1-xxxx, sodnou xxx; xxxxxx sůl pyrithionu; xxxxxxxxx xxxxx,

—

xxxxxxxxxx xx xxx 8. října 2020 xxx X-(5-xxxxx-2-xxxxxxxxxxxxxxx)-X-xxxxxxxxxxx-3-(xxxxxxxxxxxxx)-5-xxxxx-1-xxxxxx-1X-xxxxxxx-4-xxxxxxxxxx; xxxxxxxxxxxx,

—

xxxxxxxxxx xx xxx 8.&xxxx;xxxxx&xxxx;2020 pro 2-(2-xxxxxxxxxxxxx)xxxxxxx; diethylenglykolmonomethylether,

—

stanovisko ze xxx 8. října 2020 pro 4,4′-xxxxxxxxxxxxxxxxxxxx; bisfenol X,

—

xxxxxxxxxx xx xxx 8. října 2020 xxx xxxxxxxxxxxxx (XXX); X-(1-xxxxxxxxxxx)-2,6-xxxxxxx-3,4-xxxxxxx,

—

xxxxxxxxxx ze xxx 8.&xxxx;xxxxx&xxxx;2020 xxx xxxxxxxxxxxxx (XXX); (2X)-2-{2-[(2,5-xxxxxxxxxxxxxx)xxxxxx]xxxxx}-2-(xxxxxxxxxxxx)-X-xxxxxxxxxxxxxx; (X)-2-(xxxxxxxxxxxx)-X-xxxxxx-2-[α-(2,5-xxxxxxxx)-x-xxxxx]xxxxxxxx,

—

xxxxxxxxxx xx xxx 10.&xxxx;xxxxxxxx&xxxx;2020 xxx 4,4’-xxxxxxxxxxxxxxx; xxxxxxxx X,

—

xxxxxxxxxx xx dne 10.&xxxx;xxxxxxxx&xxxx;2020 pro 2-{N-ethyl-4-[(5-nitrothiazol-2-yl)azo]-m-toluidino}ethyl-acetát; X.X. Xxxxxxxx Xxxx 124,

—

xxxxxxxxxx xx xxx 10.&xxxx;xxxxxxxx&xxxx;2020 xxx xxxxxxxx xxxxxxxxxxxxxxxxxx; xxxxxxxx tridekafluorheptanovou,

—

stanovisko xx xxx 10.&xxxx;xxxxxxxx&xxxx;2020 xxx xxxxxx-X-(xxxxxxxxxxxxxxxxxx)-X-xxxxx-(3XX)-3-(4-xxxxxxxxxx)-β-xxxxxxxx; xxxxxxxxxxx,

—

xxxxxxxxxx xx dne 10.&xxxx;xxxxxxxx&xxxx;2020 xxx 6-[xxxxx-(X12-X18, xxxxxxxxxx, xxxxxxxxxx)-2,5-xxxxxxxxxxxxxxx-1-xx]xxxxxxxxx kyselinu, xxxxx x&xxxx;xxxx(2-xxxxxxxxxxxx)xxxxxx xxxx,

—

xxxxxxxxxx xx xxx 10.&xxxx;xxxxxxxx&xxxx;2020 pro 6-[xxxxx-(X10-X13, xxxxxxxxxx, xxxxxxxxxx)-2,5-xxxxxxxxxxxxxxx-1-xx]xxxxxxxxx xxxxxxxx,

—

xxxxxxxxxx xx xxx 10.&xxxx;xxxxxxxx&xxxx;2020 xxx 6-[alkyl-(C12-C18, xxxxxxxxxx, nenasycené)-2,5-dioxopyrrolidin-1-yl]hexanovou xxxxxxxx,

—

xxxxxxxxxx xx xxx 10. prosince 2020 xxx 1,3,5-triazin-2,4,6-triamin; xxxxxxx,

—

xxxxxxxxxx xx xxx 10.&xxxx;xxxxxxxx&xxxx;2020 xxx xxxxxxx xxxx: 3-(xxxxxxxxxxxxx)-1-xxxxxx-X-[(1XX,4XX,9XX)-1,2,3,4-xxxxxxxxxx-9-xxxxxxxxx-1,4-xxxxxxxxxxxxxxx-5-xx]xxxxxxx-4-xxxxxxxxxx a 3-(difluormethyl)-1-methyl-N-[(1RS,4SR,9SR)-1,2,3,4-tetrahydro-9-isopropyl-1,4-methanonaftalen-5-yl]pyrazol-4-karboxamid [xxxxxxxxx xxxxx ≥ 78 % syn-isomerů x&xxxx;≤&xxxx;15&xxxx;% xxxx-xxxxxxx], xxxxxxxxxx,

—

xxxxxxxxxx xx xxx 10.&xxxx;xxxxxxxx&xxxx;2020 xxxxxxx xxxxxxx, extraktu [x&xxxx;xxxxx xxxxxxxx Azadirachta xxxxxx, xxxxxxxxxxx xxxxx x&xxxx;xxxx xxxxxxxxxx organickými xxxxxxxxxxxx],

—

xxxxxxxxxx xx xxx 10.&xxxx;xxxxxxxx&xxxx;2020 xxx oxid xxxxxxxxx,

—

xxxxxxxxxx xx dne 10.&xxxx;xxxxxxxx&xxxx;2020 xxx xxxxxxxx (XXX), 3-xxxxxxxxx-2,1,3-xxxxxxxxxxxxxxx-4-xx-2,2-xxxxxx,

—

xxxxxxxxxx xx xxx 10.&xxxx;xxxxxxxx&xxxx;2020 ohledně xxxxxxxxxx xxxxxxxxx nových xxxxxxxxx x&xxxx;xxxxxx xxxxxxxxx xxxxxxxx 2-xxxxxxxxxxx-1-xxx; xxxxxxxxxxxxx-xxxxxxxxx-xxxxxx (XXXX) xx xxxxxx Xxxxxxxx xxxxxx.

(3)

Xxxx obdrženy xxxxxxxxx informace, xxxxx xxxxxxxxxxx xxxxxxx posouzení xxxxxxx xx xxxxxxxxxxxx XXX xx xxx 11.&xxxx;xxxxxx&xxxx;2020 xxx 2-xxxxxxxxxxxxxx xxxxxxxx x&xxxx;xxxx soli; xx xxx 11.&xxxx;xxxxxx&xxxx;2020 xxxxxxx opětovného posouzení xxxxxxxx xxxxxxxx {[(xxxxxxxxxxxxx)xxxxx]xxx(xxxxxxxxxxxxxx)}xxxxxxxxxxx xxxxxxxx x&xxxx;xxxxxx xxxxxxxxxxxx x&xxxx;xxxxxxxxxxxxxxx xxxx xx xxxxxx Xxxxxxxx komise, xx xxx 8.&xxxx;xxxxx&xxxx;2020 xxx xxxxxx xxxxxx, xx dne 10.&xxxx;xxxxxxxx&xxxx;2020 xxx xxxx xxxxxxxxx, xx dne 10.&xxxx;xxxxxxxx&xxxx;2020 xxxxxxx xxxxxxxxxx xxxxxxxxx xxxxxx informací x&xxxx;xxxxxx xxxxxxxxx xxxxxxxx 2-xxxxxxxxxxx-1-xxx; xxxxxxxxxxxxx-xxxxxxxxx-xxxxxx (EGBE) xx xxxxxx Evropské komise x&xxxx;xx xxx 10. prosince 2020 xxx xxxxxxx.

(4)

Xxxxxx xxxx xxxxxxxxx xxxxxxxxx xxxxxxxxx x&xxxx;xxxxxxxxxx xx xx xxxxxxxxxx x&xxxx;xxxx, xxx xxxxxxxxxxx xxxxxxxx xxxxxxx xxxxxxxxx xx xxxxxxxxxxxx XXX. Na xxxxxxx xxxxxxxxx xxxxxxxxxxx x&xxxx;xxxxxxxxx xxxxxxxxxxxx je xxxxx xxxxxx xxxxxx, aktualizovat xxxx xxxxxx xxxxxxxxxxxxxx xxxxxxxxxxx a označení dotčených xxxxx.

(5)

Xxxx, xx bylo Xxxxxx xxxxxxx xxxxxxxxxx XXX, xxxx obdrženy xxxxxxxxx xxxxxxxxx týkající xx xxxxxx xxxxxxxxx xxxxxxxx xxxxxxxxxx, 1,1,1-xxxxxxxxx-X-(xxxxxxxxxxxxxx)-, xxxxxxxx xxxxxxxxx x&xxxx;xxxxxx xxxxxxxxxx; xxxxxxxxxxx syntetického xxxxxxxxx xxxxx křemičitého x&xxxx;xxxxxxxxx s povrchovou úpravou. Xxxxxxxxxxx xxxxxxxxxx, 1,1,1-trimethyl-N-(trimethylsilyl)-, xxxxxxxx xxxxxxxxx x&xxxx;xxxxxx xxxxxxxxxx; xxxxxxxxxxx xxxxxxxxxxxx xxxxxxxxx oxidu xxxxxxxxxxx x&xxxx;xxxxxxxxx x&xxxx;xxxxxxxxxx úpravou xxxx xxxxxx inhalační xxxxxxxx xxxxxxxxx 2, xxxxxxxxxx ve xxxxxxxxxx XXX ze xxx 5.&xxxx;xxxxxxxx&xxxx;2019, xx xxxxxx xxx xxxxxxxx xx xxxxxxx XX xxxxxxxx (XX) x.&xxxx;1272/2008, xxxxx Xxxxxx xxxx xxxxxxx xxxxxxxxx xxxxxxxxx x&xxxx;xxxxxxxxxx, xx xx xxxx xxxxx xxxxx posouzení XXX. Do xxxxxxx XX xxxxxxxx (XX) x.&xxxx;1272/2008 xx však xxxx být xxxxxxxx xxxxxxxxxxx této xxxxx xxxx XXXX XX 2, doporučená xx xxxxxxxxxx xxxxxx XXX xx xxx 5. prosince 2019, xxxxx xxxxxx xxxxxxxx xxxxx xxxx xxxxxxxxx, xxxxx xx xxxxxxxxxx xxxxx xxxxxxxxx xxxx xxxxxxxxxxx.

(6)

Xxxxxxxx (XX) x.&xxxx;1272/2008 xx xxxxx xxxx xxx xxxxxxxxxxxxx způsobem xxxxxxx.

(7)

Xxxxxxxxxx xxxxxx xxxx xxxxxxxxxxxxxxx xxxxxxxxxxxxxxx klasifikací xx nemělo xxx xxxxxxxxxx xxxxx, xxxxxxx xxxxxxxxxx xxxxxxxxx určitou xxxx xx to, xxx xxxxxxxxxxxx označování x&xxxx;xxxxxx xxxxx x&xxxx;xxxxx xxxxx xxxx xxxxxxxxxxxxxx xxxxxxxxxxxx a prodali stávající xxxxxx, na xxxxx xx xxxxxxxx xxxxxxxxx xxxxxxxxxxx xxxxxxxxx. Xxxx xxxx xx xxxxxx xxxxxxxx x&xxxx;xxxx, aby xxxxxxxxxx měli dostatek xxxx xxxxxxxx xxxxxxxx xxxxx k zajištění xxxxxxxx xxxxxxxxxx xxxxxxx xxxxxxxx xxxxxxxxx, které xxxxxxxx x&xxxx;xxxxxxxx xxxx xxxxxxxxxxx xxxxx tohoto xxxxxxxx. Xxxxxxxxxxx by xxxx xxxx být umožněno xxxxxxxx xxxx xxxx xxxxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxx x&xxxx;xxxxxxxxxxxxx xxxxxxxx přizpůsobit xxxxxxxxxx x&xxxx;xxxxxx na xxxxxxxxxxx xxxxxxx xxxx xxxxx xxxxxxxxxxxxx xxxxxx xxxxxxxx, xxx xxxx xxxxxxxxx xxxxxx xxxxxx xxxxxxx xxxxxxxx xxxxxx x&xxxx;xxxxxxxxx xxxxxxxxx a aby xx xxxxxxxxxxx xxxxxxxx xxxxxxxxxx xxxxxxxx,

XXXXXXX XXXX XXXXXXXX:

Článek 1

Změny nařízení (XX) x.&xxxx;1272/2008

Xxxxxxx XX nařízení (XX) x.&xxxx;1272/2008 xx xxxx v souladu x&xxxx;xxxxxxxx xxxxxx xxxxxxxx.

Článek 2

Vstup x&xxxx;xxxxxxxx x&xxxx;xxxxxxxxxxxx

Xxxx xxxxxxxx vstupuje v platnost xxxxxxxx xxxx po xxxxxxxxx v Úředním xxxxxxxx Xxxxxxxx unie.

Použije xx xxx xxx 23.&xxxx;xxxxxxxxx 2023.

Xxxxxxxx xx druhého xxxxxxxxxxx xxxxxx xxxxxx xxxxx být xxxxx x&xxxx;xxxxx xxxxxxxxxxxxx, xxxxxxxxxx x&xxxx;xxxxxx x&xxxx;xxxxxxx x&xxxx;xxxxx xxxxxxxxx xxx dne xxxx vstupu x&xxxx;xxxxxxxx.

Xxxx xxxxxxxx xx xxxxxxx v celém rozsahu x&xxxx;xxxxx xxxxxxxxxx xx xxxxx xxxxxxxxx státech.

V Bruselu xxx 16. února 2022.

Xx Xxxxxx

xxxxxxxxxxx

Xxxxxx VON XXX XXXXX

(1)&xxxx;&xxxx;Xx. xxxx. X&xxxx;353, 31.12.2008, x.&xxxx;1.

(2)&xxxx;&xxxx;Xxxxxxxxxx jsou xxxxxxxx xx xxxx xxxxxxxxxxx stránce: https://echa.europa.eu/registry-of-clh-intentions-until-outcome/-/dislist/name/-/ecNumber/-/casNumber/-/dte_receiptFrom/-/dte_receiptTo/-/prc_public_status/Opinion+Adopted/dte_withdrawnFrom/-/dte_withdrawnTo/-/sbm_expected_submissionFrom/-/sbm_expected_submissionTo/-/dte_finalise_deadlineFrom/-/dte_finalise_deadlineTo/-/haz_addional_hazard/-/lec_submitter/-/dte_assessmentFrom/-/dte_assessmentTo/-/prc_regulatory_programme/-/. – Xxxxxxxxxx xx xxx 11.&xxxx;xxxxxx&xxxx;2020 a ze xxx 10.&xxxx;xxxxxxxx&xxxx;2020 xxxxxxxx xx xxxxxxxxxx xxxxxxxxx xx žádost Xxxxxxxx xxxxxx jsou x&xxxx;xxxxxxxxx xx této xxxxxxxxxxx xxxxxxx: https://echa.europa.eu/about-us/who-we-are/committee-for-risk-assessment/opinions-of-the-rac-adopted-under-specific-echa-s-executive-director-requests

XXXXXXX

Xxxxxxx XX xxxxxxxx (XX) x.&xxxx;1272/2008 xx xxxx takto:

1)

v části 3 xx tabulka 3 xxxx takto:

a)

vkládají xx xxxx xxxxxxx:

Xxxxxxxx číslo

Chemický xxxxx

Xxxxx XX

Xxxxx XXX

Xxxxxxxxxxx

Xxxxxxxx

Xxxxxxxxxx xxxxxxx. limity, multiplikační xxxxxxx x&xxxx;XXX

Xxxxxxxx

Xxxx tříd x&xxxx;xxxxxxxxx xxxxxxxxxxxxx

Xxxx xxxxxxxxxxxx xxx o nebezpečnosti

Kódy xxxxxxxxxxx xxxxxxx x&xxxx;xxxxxxxxxx xxxx

Xxxx xxxxxxxxxxxx vět x&xxxx;xxxxxxxxxxxxx

Xxxx xxxxx. xxxxxxxxxxxx xxx x&xxxx;xxxxxxxxxxxxx

„014-052-00-7

xxxxxxxxx, 1,1,1-trimethyl-N-(trimethylsilyl)-, xxxxxxxx xxxxxxxxx x&xxxx;xxxxxx xxxxxxxxxx; xxxxxxxxx syntetický xxxxxxx xxxx xxxxxxxxx x&xxxx;xxxxxxxxx x&xxxx;xxxxxxxxxx úpravou

272-697-1

68909-20-6

STOT XX 2

X373 (plíce) (vdechování)

GHS08

Wng

H373 (xxxxx) (vdechování)

EUH066“

„035-005-00-7

bromid xxxxxx

235-183-8

12124-97-9

Xxxx. 1X

Xxxx.

XXXX SE 3

XXXX XX 1

Eye Irrit. 2

X360XX

X362

X336

X372 (xxxxxxx xxxxxx)

X319

XXX08

XXX07

Xxx

X360XX

X362

X336

X372 (xxxxxxx xxxxxx)

X319“

„050-032-00-4

xxxxxxxxxx-xxx(2-xxxxxxxxxxxxx)

220-481-2

2781-10-4

Xxxx. 2

Xxxx. 1X

XXXX XX 1

X341

X360XX

X372 (xxxxxxxx systém)

GHS08

Dgr

H341

H360FD

H372 (xxxxxxxx xxxxxx)“

„050-033-00-X

xxxxxxxxxx-xxxxxxxx

213-928-8

1067-33-0

Xxxx. 2

Xxxx. 1B

STOT XX 1

H341

H360FD

H372 (xxxxxxxx xxxxxx)

XXX08

Xxx

X341

X360XX

X372 (xxxxxxxx xxxxxx)“

„052-001-00-0

xxxxxx

236-813-4

13494-80-9

Xxxx. 1X

Xxxx.

X360Xx

X362

XXX08

Xxx

X360Xx

X362“

„052-002-00-6

xxxx xxxxxxxxxxx

231-193-1

7446-07-3

Xxxx. 1X

Xxxx.

X360Xx

X362

XXX08

Xxx

X360Xx

X362“

„056-005-00-3

xxxxxxxxx xxxxxxx-xxxxxxxx

237-222-4

13701-59-2

Xxxx. 1X

Xxxxx Xxx. 4

Xxxxx Tox. 3

H360FD

H332

H301

GHS08

GHS06

Dgr

H360FD

H332

H301

inhalační:

ATE = 1,5&xxxx;xx/x (xxxxx xxxx xxxx)

xxxxxx:

XXX&xxxx;= 100 mg/kg XX“

„601-097-00-8

xxxxxxxxxxxx

203-132-9

103-65-1

Xxxx. Xxx. 3

Xxx. Xxx. 1

XXXX XX 3

Xxxxxxx Xxxxxxx 2

X226

X304

X335

X411

XXX02

XXX08

XXX07

XXX09

Xxx

X226

X304

X335

X411“

„603-243-00-6

xxxxxxxxxxxxxx 2,2-xxxxxxxxxxxxxx-1-xxx; 3-xxxx-2,2-xxx(xxxxxxxxxx)xxxxxx-1-xx

253-057-0

36483-57-5; 1522-92-5

Xxxx. 1X

Xxxx. 2

X350

X341

XXX08

Xxx

X350

X341“

„604-096-00-0

xxxxxxxxxxxxxxxx (ISO); 5-{[2-(2-xxxxxxxxxxxx)xxxxxx]xxxxxx}-6-xxxxxx-1,3-xxxxxxxxxxx

200-076-7

51-03-6

XXXX XX 3

Xxx Irrit. 2

Xxxxxxx Xxxxx 1

Xxxxxxx Xxxxxxx 1

X335

X319

X400

X410

XXX07

XXX09

Xxx

X335

X319

X410

XXX066

X&xxxx;= 1

X&xxxx;= 1“

„604-097-00-6

2,4,6-xxx-xxxx-xxxxxxxxxx

211-989-5

732-26-3

Xxxx. 1X

Xxxxx Tox. 4

XXXX XX 2

Xxxx Xxxx. 1B

H360D

H302

H373 (játra)

H317

GHS08

GHS07

Dgr

H360D

H302

H373 (xxxxx)

X317

xxxxxx:

XXX&xxxx;= 500&xxxx;xx/xx XX“

„604-098-00-1

4,4’-xxxxxxxxxxxxxxx; xxxxxxxx S

201-250-5

80-09-1

Repr. 1X

X360XX

XXX08

Xxx

X360XX“

„606-153-00-5

xxxxxxxxxx

204-337-6

119-61-9

Xxxx. 1X

X350

XXX08

Xxx

X350“

„606-154-00-0

xxxxxxxxxxx (XXX); 2-amino-3-chlor-1,4-naftochinon

220-529-2

2797-51-5

Carc. 2

Xxxx. 2

Xxxxx Xxx. 4

XXXX RE 2

Xxx Xxxxx. 2

Skin Xxxx. 1&xxxx;X

Xxxxxxx Xxxxx 1

Xxxxxxx Xxxxxxx 1

X351

X361x

X302

X373 (krevní xxxx, ledviny)

H319

H317

H400

H410

GHS08

GHS07

GHS09

Wng

H351

H361d

H302

H373 (krevní xxxx, ledviny)

H319

H317

H410

orální:

ATE = 500&xxxx;xx/xx XX

X&xxxx;= 10

X&xxxx;= 10“

„607-756-00-6

xxx-1,7,7-xxxxxxxxxxxxxxxx[2.2.1]xxxx-2-xx-xxxxxxx; xxxxxxxxx-xxxxxxx

227-561-6

5888-33-5

Xxxx Xxxx. 1&xxxx;X

X317

XXX07

Xxx

X317“

„607-757-00-1

xxxxxxxxx (XXX); 4-(2,2-dimethylhydrazino)-4-oxobutanová xxxxxxxx; X-(xxxxxxxxxxxxx)xxxxxxxxxxx kyselina

216-485-9

1596-84-5

Carc. 2

H351

GHS08

Wng

H351“

„607-758-00-7

4,4′-oxydi(benzensulfonohydrazid)

201-286-1

80-51-3

Self-react. X

Xxxxxxx Acute 1

Aquatic Xxxxxxx 1

H242

H400

H410

GHS02

GHS09

Dgr

H242

H410

M = 1

X&xxxx;= 1“

„607-759-00-2

xxxxxx-4-xxxxxxxxxxxxxxx

216-407-3

1576-35-8

Xxxx-xxxxx. X

X242

XXX02

Xxx

X242“

„607-760-00-8

2-{X-xxxxx-4-[(5-xxxxxxxxxxxx-2-xx)xxx]-x-xxxxxxxxx}xxxxx-xxxxxx; X.X. Xxxxxxxx Blue 124

239-203-6

15141-18-1

Xxxx Xxxx. 1&xxxx;X

X317

XXX07

Xxx

X317

Xxxx Xxxx. 1&xxxx;X; X317: X&xxxx;≥&xxxx;0,001&xxxx;%“

„607-761-00-3

xxxxxxxxxxxxxxxxx xxxxxxxx; xxxxxxxxxxxxxxxxxxxxx xxxxxxxx

206-798-9

375-85-9

Xxxx. 1X

XXXX XX 1

H360D

H372 (xxxxx)

XXX08

Xxx

X360X

X372 (játra)“

„607-762-00-9

methyl-N-(isopropoxykarbonyl)-L-valyl-(3RS)-3-(4-chlorfenyl)-β-alaninát; xxxxxxxxxxx

-

283159-90-0

Xxxx. 2

Xxxxxxx Xxxxxxx 2

X351

X411

XXX08

XXX09

Xxx

X351

X411“

„607-763-00-4

6-[xxxxx-(X12-X18, xxxxxxxxxx, xxxxxxxxxx)-2,5-xxxxxxxxxxxxxxx-1-xx]xxxxxxxx kyselina, xxxxx x&xxxx;xxxx(2-xxxxxxxxxxxx)xxxxxx soli

-

-

Repr. 1X

Xxx Irrit. 2

H360FD

H319

GHS08

GHS07

Dgr

H360FD

H319“

„607-764-00-X

6-[alkyl-(C10-C13, xxxxxxxxxx, xxxxxxxxxx)-2,5-xxxxxxxxxxxxxxx-1-xx]xxxxxxxx kyselina

-

2156592-54-8

Repr. 1X

Xxx Irrit. 2

X360XX

X319

XXX08

XXX07

Xxx

X360XX

X319“

„607-765-00-5

6-[xxxxx-(X12-X18, xxxxxxxxxx, nenasycené)-2,5-dioxopyrrolidin-1-yl]hexanová kyselina

-

-

Repr. 1X

X360XX

XXX08

Xxx

X360XX“

„613-341-00-0

xxxxxxxxxxx (XXX); 3,6-xxx(x-xxxxxxxxxx)-1,2,4,5-xxxxxxxx

277-728-2

74115-24-5

Xxxxxxx Xxxxxxx 1

H410

GHS09

Wng

H410

M = 1“

„613-342-00-6

theofylin; 1,3-xxxxxxxx-3,7-xxxxxxx-1X-xxxxx-2,6-xxxx

200-385-7

58-55-9

Xxxx. 1X

X360X

XXX08

Xxx

X360X“

„613-343-00-1

xxxxxxxxx (ISO); 2,6-xxxxxxx-4-(3,3-xxxxxxxxxxxxxxx)xxxxx{3-[5-(xxxxxxxxxxxxxx)-2-xxxxxxxxxx]xxxxxx}xxxxx

-

179101-81-6

Xxxx Xxxx. 1

Xxxxxxx Xxxxx 1

Xxxxxxx Xxxxxxx 1

X317

X400

X410

XXX07

XXX09

Xxx

X317

X410

X&xxxx;= 1&xxxx;000

X&xxxx;= 100“

„613-344-00-7

pyridin-2-thiol-1-oxid, xxxxx xxx; xxxxx xxx xxxxxxxxxx; pyrithion xxxxx

223-296-5;

240-062-8

3811-73-2;

15922-78-8

Xxxxx Xxx. 3

Xxxxx Xxx. 3

Xxxxx Xxx. 4

XXXX XX 1

Xxxx Xxxxx. 2

Xxx Xxxxx. 2

Xxxx Xxxx. 1

Aquatic Xxxxx 1

Xxxxxxx Xxxxxxx 2

X331

X311

X302

X372 (nervový systém)

H315

H319

H317

H400

H411

GHS06

GHS08

GHS09

Dgr

H331

H311

H302

H372 (xxxxxxx xxxxxx)

X315

X319

X317

X410

XXX070

xxxxxxxxx:

XXX&xxxx;= 0,5&xxxx;xx/x (xxxxx nebo mlha)

dermální:

ATE = 790&xxxx;xx/xx TH

orální:

ATE = 500&xxxx;xx/xx XX

X&xxxx;= 100“

„613-345-00-2

1,3,5-xxxxxxx-2,4,6-xxxxxxx;

xxxxxxx

203-615-4

108-78-1

Xxxx. 2

XXXX XX 2

X351

X373 (močové xxxxx)

XXX08

Xxx

X351

X373 (xxxxxx xxxxx)“

„615-046-00-2

1,3-xxx(1-xxxxxxxxxx-1-xxxxxxxxxxx)xxxxxx; [x-XXXXX]

220-474-4

2778-42-9

Xxxx. Xxxx. 1

Skin Xxxx. 1 A

H334

H317

GHS08

Dgr

H334

H317“

„615-047-00-8

1,3-bis(isokyanatomethyl)benzen; [x-XXX]

222-852-4

3634-83-1

Xxxx. Xxxx. 1

Skin Sens. 1&xxxx;X

X334

X317

XXX08

Xxx

X334

X317

Xxxx Xxxx. 1 A; X317: C ≥ 0,001 %“

„615-048-00-3

2,4,6-triisopropyl-m-fenylen-diisokyanát

218-485-4

2162-73-4

Resp. Sens. 1

Xxxx Xxxx. 1

H334

H317

GHS08

Dgr

H334

H317“

„615-049-00-9

1,5-diisokyanatonaftalen

[obsahující &xx;&xxxx;0,1&xxxx;% xxxx. xxxxxx x&xxxx;xxxxxxxxxxxxxx průměrem menším xxx 50 μm]

221-641-4

3173-72-6

STOT XX 3

Skin Xxxxx. 2

Xxx Irrit. 2

Xxxx. Xxxx. 1

Xxxx Xxxx. 1&xxxx;X

Xxxxxxx Chronic 3

X335

X315

X319

X334

X317

X412

XXX07

XXX08

Xxx

X335

X315

X319

X334

X317

X412“

„615-050-00-4

1,5-xxxxxxxxxxxxxxxxxxxx

[xxxxxxxxxx &xx;&xxxx;0,1&xxxx;% hmot. xxxxxx x&xxxx;xxxxxxxxxxxxxx xxxxxxxx xxxxxx xxx 50 μx]

221-641-4

3173-72-6

Xxxxx Xxx. 2

XXXX XX 3

Xxxx Xxxxx. 2

Xxx Xxxxx. 2

Resp. Sens. 1

Xxxx Xxxx. 1&xxxx;X

Xxxxxxx Xxxxxxx 3

X330

X335

X315

X319

X334

X317

X412

XXX06

XXX08

Xxx

X330

X335

X315

X319

X334

X317

X412

xxxxxxxxx:

XXX&xxxx;= 0,27&xxxx;xx/x (xxxxx xxxx mlha)“

„616-237-00-3

fluopikolid (XXX); 2,6-xxxxxxx-X-[3-xxxxx-5-(xxxxxxxxxxxxxx)-2-xxxxxxx]xxxxxxxxxxxxxx

-

239110-15-7

Xxxx. 2

H361d

GHS08

Wng

H361d“

„616-238-00-9

triamid xxxxxxxx X-(2-xxxxxxxxxx)xxxxxxxxxx

477-690-9

874819-71-3

Xxxx. 1X

XXXX XX 2

X360Xx

X373 (ledviny)

GHS08

Dgr

H360Fd

H373 (xxxxxxx)“

„616-239-00-4

X-(5-xxxxx-2-xxxxxxxxxxxxxxx)-X-xxxxxxxxxxx-3-(xxxxxxxxxxxxx)-5-xxxxx-1-xxxxxx-1X-xxxxxxx-4-xxxxxxxxxx; isoflucypram

-

1255734-28-1

Repr. 2

Xxxxx Xxx. 4

Xxxx Xxxx. 1X

Xxxxxxx Acute 1

Aquatic Xxxxxxx 1

X361x

X332

X317

X400

X410

XXX08

XXX07

XXX09

Xxx

X361x

X332

X317

X410

xxxxxxxxx:

XXX&xxxx;= 2,2 mg/l (xxxxx xxxx xxxx)

X&xxxx;= 10

X&xxxx;= 1“

„616-240-00-X

reakční xxxx: 3-(xxxxxxxxxxxxx)-1-xxxxxx-X-[(1XX,4XX,9XX)-1,2,3,4-xxxxxxxxxx-9-xxxxxxxxx-1,4-xxxxxxxxxxxxxxx-5-xx]xxxxxxx-4-xxxxxxxxxx a 3-(difluormethyl)-1-methyl-N-[(1RS,4SR,9SR)-1,2,3,4-tetrahydro-9-isopropyl-1,4-methanonaftalen-5-yl]pyrazol-4-karboxamid [xxxxxxxxx xxxxx ≥&xxxx;78&xxxx;% syn-isomerů x&xxxx;≤&xxxx;15&xxxx;% anti-isomerů], xxxxxxxxxx

-

881685-58-1

Xxxx. 2

Xxxx. 1X

Xxxx Xxxx. 1X

Xxxxxxx Xxxxx 1 Xxxxxxx Xxxxxxx 1

X351

X360X

X317

X400

X410

XXX08

XXX07

XXX09

Xxx

X351

X360X

X317

X410

Xxxx. 1X; X360X:

X&xxxx;≥&xxxx;3&xxxx;%

X&xxxx;= 10

X&xxxx;= 10“

„650-058-00-1

Xxxxxxx, extrakt [x&xxxx;xxxxx xxxxxxxx Xxxxxxxxxxx indica, xxxxxxxxxxx vodou a dále xxxxxxxxxx xxxxxxxxxxx rozpouštědly]

283-644-7

84696-25-3

Repr. 2

Xxxx Xxxx. 1

Xxxxxxx Xxxxxxx 1

X361x

X317

X410

XXX08

XXX07

XXX09

Xxx

X361x

X317

X410

X&xxxx;= 10“

b)

položky xxxxxxxxxxxx xxxxxxxxx xxxxxx 014-001-00-9; 023-001-00-8; 601-024-00-X; 603-014-00-0; 603-107-00-6; 604-030-00-0; 607-111-00-9; 607-230-00-6; 607-253-00-1; 607-254-00-7; 607-734-00-6; 607-735-00-1; 607-736-00-7; 608-032-00-2; 609-042-00-X; 613-012-00-1; 616-164-00-7 xx xxxxxxxxx těmito xxxxxxxxx:

Xxxxxxxx xxxxx

Xxxxxxxx xxxxx

Xxxxx XX

Xxxxx XXX

Xxxxxxxxxxx

Xxxxxxxx

Xxxxxxxxxx xxxxxxx. xxxxxx, xxxxxxxxxxxxx xxxxxxx a ATE

Poznámky

Kódy xxxx x&xxxx;xxxxxxxxx xxxxxxxxxxxxx

Xxxx xxxxxxxxxxxx vět o nebezpečnosti

Kódy xxxxxxxxxxx xxxxxxx x&xxxx;xxxxxxxxxx xxxx

Xxxx xxxxxxxxxxxx vět x&xxxx;xxxxxxxxxxxxx

Xxxx xxxxx. standardních xxx x&xxxx;xxxxxxxxxxxxx

„014-001-00-9

xxxxxxxxxxxxx

233-042-5

10025-78-2

Xxxx. Xxx. 1

Xxxxx-xxxxx. 1

Acute Xxx. 3

Xxxxx Xxx. 4

Xxxx Xxxx. 1&xxxx;X

Xxx Xxx. 1

X224

X260

X331

X302

X314

X318

XXX02

XXX06

XXX05

Xxx

X224

X260

X331

X302

X314

XXX014

XXX029

XXX071

xxxxxxxxx:

XXX&xxxx;= 7,6&xxxx;xx/x (xxxx)

xxxxxx:

XXX&xxxx;= 1&xxxx;000 &xxxx;xx/xx XX“

„023-001-00-8

xxxx xxxxxxxxx

215-239-8

1314-62-1

Xxxx. 2

Xxxx. 1X

Xxxx. 2

Xxxx.

Xxxxx Xxx. 3

Xxxxx Xxx. 2

XXXX SE 3

XXXX XX 1

Xxxxxxx Xxxxxxx 2

X341

X350

X361xx

X362

X301

X330

X335

X372 (xxxxxxx xxxxx, vdechování)

H411

GHS06

GHS08

GHS09

Dgr

H341

H350

H361fd

H362

H301

H330

H335

H372 (xxxxxxx xxxxx, vdechování)

H411

inhalační:

ATE = 0,05&xxxx;xx/x (xxxxx xxxx mlha)

orální:

ATE = 220&xxxx;xx/xx TH“

„601-024-00-X

kumen

202-704-5

98-82-8

Flam. Xxx. 3

Xxxx. 1X

Xxx. Xxx. 1

XXXX SE 3

Xxxxxxx Xxxxxxx 2

X226

X350

X304

X335

X411

XXX02

XXX08

XXX07

XXX09

Xxx

X226

X350

X304

X335

X411“

„603-014-00-0

2-xxxxxxxxxxx-1-xx; xxxxxxxxxxxxx-xxxxxxxxx-xxxxx

203-905-0

111-76-2

Xxxxx Xxx. 3

Xxxxx Tox. 4

Xxxx Xxxxx. 2

Xxx Xxxxx. 2

X331

X302

X315

X319

XXX06

Xxx

X331

X302

X315

X319

xxxxxxxxx:

XXX&xxxx;= 3&xxxx;xx/x (xxxx)

xxxxxx:

XXX&xxxx;= 1&xxxx;200 &xxxx;xx/xx XX“

„603-107-00-6

2-(2-xxxxxxxxxxxxx)xxxxxxx; xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx

203-906-6

111-77-3

Xxxx. 1X

X360X

XXX08

Xxx

X360X

Xxxx. 1X; H360D: X&xxxx;≥&xxxx;3&xxxx;%“

„604-030-00-0

4,4′-xxxxxxxxxxxxxxxxxxxx; xxxxxxxx A

201-245-8

80-05-7

Repr. 1B

STOT XX 3

Eye Xxx. 1

Xxxx Sens. 1

Aquatic Xxxxx 1

Aquatic Xxxxxxx 1

X360X

X335

X318

X317

X400

X410

XXX08

XXX07

XXX05

XXX09

Xxx

X360X

X335

X318

X317

X410

X&xxxx;= 1

M = 10“

„607-111-00-9

2-xxxxx-2-{[(1-xxxxxxxx)xxx]xxxxxx}xxxxxx-1,3-xxxx-xxxxxxxxx; 2,2-xxx(xxxxxxxxxxxxxxxxx)xxxxx-xxxxxxx;

xxxxxxxxxxxxxxxxx-xxxxxxxxxx

239-701-3

15625-89-5

Xxxx. 2

Xxxx Irrit. 2

Xxx Xxxxx. 2

Skin Xxxx. 1

Aquatic Xxxxx 1

Xxxxxxx Chronic 1

X351

X315

X319

X317

X400

X410

XXX08

XXX07

XXX09

Xxx

X351

X315

X319

X317

X410

X&xxxx;= 1

X&xxxx;= 1

D“

„607-230-00-6

2-ethylhexanová xxxxxxxx x&xxxx;xxxx xxxx, x&xxxx;xxxxxxxx xxxx, xxxxx xxxx xxxxxxx xxxxx x&xxxx;xxxx xxxxxxx

-

-

Xxxx. 1B

H360D

GHS08

Dgr

H360D“

„607-253-00-1

cyfluthrin (XXX); [(3-xxxxxx-4-xxxxxxxxxx)xxxxxxxxxx]-3-(2,2-xxxxxxxxxxxx)-2,2-xxxxxxxxxxxxxxxxxxx-1-xxxxxxxxxx

269-855-7

68359-37-5

Xxxx.

Xxxxx Tox. 2

Acute Xxx. 2

XXXX XX 1

Xxxxxxx Acute 1

Aquatic Xxxxxxx 1

X362

X330

X300

X370 (xxxxxxx xxxxxx)

X400

X410

XXX06

XXX08

XXX09

Xxx

X362

X330

X300

X370 (nervový xxxxxx)

X410

xxxxxxxxx:

XXX&xxxx;= 0,14&xxxx;xx/x (xxxxx xxxx xxxx)

xxxxxx:

XXX&xxxx;= 14&xxxx;xx/xx XX

X&xxxx;= 1&xxxx;000&xxxx;000

X&xxxx;= 1&xxxx;000&xxxx;000 “

„607-254-00-7

β-cyfluthrin (XXX); xxxxxxx směs: xxx-(X)-xxxx(4-xxxxx-3-xxxxxxxxxxx)xxxxxx-(1X,3X)-3-(2,2-xxxxxxxxxxxxxx)-2,2-xxxxxxxxxxxxxxxxxxx-1-xxxxxxxxxx x&xxxx;xxx-(X)-xxxx(4-xxxxx-3-xxxxxxxxxxx)xxxxxx-(1X,3X)-3-(2,2-xxxxxxxxxxxxxx)-2,2-xxxxxxxxxxxxxxxxxxx-1-xxxxxxxxxx

-

1820573-27-0

Xxxx.

Xxxxx Xxx. 2

Xxxxx Xxx. 2

XXXX XX 1

Xxxxxxx Acute 1

Xxxxxxx Xxxxxxx 1

H362

H330

H300

H370 (xxxxxxx xxxxxx)

X400

X410

XXX06

XXX08

XXX09

Xxx

X362

X330

X300

X370 (xxxxxxx xxxxxx)

X410

xxxxxxxxx:

XXX&xxxx;= 0,081&xxxx;xx/x (xxxxx xxxx xxxx)

xxxxxx:

XXX&xxxx;= 11&xxxx;xx/xx XX

X&xxxx;= 1 000 000

M = 1&xxxx;000&xxxx;000 “

„607-734-00-6

xxxxxxxxxxx-2,2‘,2“,2“‘,2“&xxxx;“ -(ethan-1,2-diylnitrilo)pentaacetát

404-290-3

7216-95-7

Repr. 1X

Xxxxx Xxx. 4

STOT XX 2

Xxx Irrit. 2

X360X

X332

X373 (xxxxxxxxxx)

X319

XXX08

XXX07

Xxx

X360X

X332

X373 (vdechování)

H319

Repr. 1B; X360X: C ≥ 3 %

inhalační:

ATE = 1,5 mg/l (xxxxx xxxx xxxx)“

„607-735-00-1

{[(xxxxxxxxxxxxx)xxxxx]xxx(xxxxxxxxxxxxxx)}xxxxxxxxxxx xxxxxxxx

200-652-8

67-43-6

Xxxx. 1X

Xxxxx Xxx. 4

XXXX XX 2

Xxx Xxxxx. 2

X360X

X332

X373 (xxxxxxxxxx)

X319

XXX08

XXX07

Xxx

X360X

X332

X373 (xxxxxxxxxx)

X319

Xxxx. 1X; H360D: X&xxxx;≥&xxxx;3&xxxx;%

xxxxxxxxx:

XXX&xxxx;= 1,5&xxxx;xx/x (xxxxx xxxx xxxx)“

„607-736-00-7

xxxxxxxxxxxx-[(xxxxxxxxxxxxxxxxx)xxxxxxxx(xxxxxxxxxxxxxx)xxxxxxxxxxx]

205-391-3

140-01-2

Xxxx. 1X

Xxxxx Xxx. 4

STOT XX 2

X360X

X332

X373 (xxxxxxxxxx)

XXX08

XXX07

Xxx

X360X

X332

X373 (vdechování)

Repr. 1X; H360D: C ≥ 3 %

inhalační:

ATE = 1,5&xxxx;xx/x (xxxxx nebo xxxx)“

„608-032-00-2

xxxxxxxxxxx (XXX); (1X)-X-[(6-xxxxxxxxxxxx-3-xx)xxxxxx]-X’-xxxx-X-xxxxxxxxxxxxxxxxxxx; (X)-X 1-[(6-xxxxx-3-xxxxxxx)xxxxxx]-X 2-xxxx-X 1-xxxxxxxxxxxxxxxx

-

135410-20-7&xxxx;160430-64-8

Xxxx. 2

Acute Xxx. 3

Xxxxxxx Xxxxxxx 1

Xxxxxxx Xxxxx 1

X361x

X301

X410

X400

XXX08

XXX06

XXX09

Xxx

X361x

X301

X410

xxxxxx:

XXX&xxxx;= 140&xxxx;xx/xx XX

X&xxxx;= 10

X&xxxx;= 10“

„609-042-00-X

pendimethalin (XXX); X-(1-xxxxxxxxxxx)-2,6-xxxxxxx-3,4-xxxxxxx

254-938-2

40487-42-1

Xxxx. 2

Aquatic Xxxxx 1

Aquatic Xxxxxxx 1

X361x

X400

X410

XXX08

XXX09

Xxx

X361x

X410

X&xxxx;= 100

X&xxxx;= 10“

„613-012-00-1

bentazon (XXX); 3-xxxxxxxxx-1X-2,1,3-xxxxxxxxxxxxxxx-4(3X)-xx-2,2-xxxxxx

246-585-8

25057-89-0

Xxxx. 2

Xxxxx Xxx. 4

Eye Xxxxx. 2

Xxxx Xxxx. 1

H361d

H302

H319

H317

GHS08

GHS07

Wng

H361d

H302

H319

H317

orální: XXX&xxxx;= 1 600 &xxxx;xx/xx XX“

„616-164-00-7

xxxxxxxxxxxxx (XXX); (2E)-2-{2-[(2,5-dimethylfenoxy)methyl]fenyl}-2-(methoxyimino)-N-methylacetamid; (X)-2-(xxxxxxxxxxxx)-X-xxxxxx-2-[α-(2,5-xxxxxxxx)-x-xxxxx]xxxxxxxx

149961-52-4

Xxxx. 2

Xxxx. 2

Acute Xxx. 4

Xxxxxxx Acute 1

Xxxxxxx Xxxxxxx 1

H351

H361d

H332

H400

H410

GHS08

GHS07

GHS09

Wng

H351

H361d

H332

H410

inhalační:

ATE = 1,3&xxxx;xx/x (xxxxx nebo xxxx)

X&xxxx;= 100

M = 100“

x)

xxxxxxx xxxxxxxxxxxx indexovému xxxxx 615-007-00-X xx xxxxxxx.